Bioventus Inc.
BVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $0 |
| % Growth | 11.9% | 0% | 18.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 67.7% | 64.1% | 64.6% | 70.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -2.1% | -16% | -32.7% | 2.8% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | -$0 | $0 | -$0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -5.9% | -30.5% | -31% | 4.5% |
| EPS | -0.52 | -2.49 | -2.59 | -0.15 |
| % Growth | 79.1% | 3.9% | -1,626.7% | – |
| EPS Diluted | -0.52 | -2.49 | -2.59 | -0.15 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | $0 |
| % Margin | 6.8% | -4.5% | -23.7% | 10.6% |